JP2017508475A5 - - Google Patents

Download PDF

Info

Publication number
JP2017508475A5
JP2017508475A5 JP2016559286A JP2016559286A JP2017508475A5 JP 2017508475 A5 JP2017508475 A5 JP 2017508475A5 JP 2016559286 A JP2016559286 A JP 2016559286A JP 2016559286 A JP2016559286 A JP 2016559286A JP 2017508475 A5 JP2017508475 A5 JP 2017508475A5
Authority
JP
Japan
Prior art keywords
amino acid
acid sequence
antigen
seq
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016559286A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017508475A (ja
JP6865585B2 (ja
Filing date
Publication date
Priority claimed from GB1405475.3A external-priority patent/GB2524552B/en
Priority claimed from GB1405477.9A external-priority patent/GB2524553C/en
Application filed filed Critical
Priority claimed from PCT/EP2015/056654 external-priority patent/WO2015144855A1/en
Publication of JP2017508475A publication Critical patent/JP2017508475A/ja
Publication of JP2017508475A5 publication Critical patent/JP2017508475A5/ja
Priority to JP2021064572A priority Critical patent/JP7607498B2/ja
Application granted granted Critical
Publication of JP6865585B2 publication Critical patent/JP6865585B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016559286A 2014-03-26 2015-03-26 成長分化因子１５（ｇｄｆ−１５）に対するモノクローナル抗体およびがん悪液質およびがんを処置するためのその使用 Active JP6865585B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021064572A JP7607498B2 (ja) 2014-03-26 2021-04-06 成長分化因子１５（ｇｄｆ－１５）に対するモノクローナル抗体およびがん悪液質およびがんを処置するためのその使用

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB1405475.3A GB2524552B (en) 2014-03-26 2014-03-26 Monoclonal antibodies to growth and differentiation factor 15 (GDF-15), and use thereof for treating cancer
GB1405477.9A GB2524553C (en) 2014-03-26 2014-03-26 Monoclonal antibodies to growth and differentiation factor 15 (GDF-15), and uses thereof for treating cancer cachexia
GB1405477.9 2014-03-26
GB1405475.3 2014-03-26
PCT/EP2015/056654 WO2015144855A1 (en) 2014-03-26 2015-03-26 Monoclonal antibodies to growth and differentiation factor 15 (gdf-15), and uses thereof for treating cancer cachexia and cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021064572A Division JP7607498B2 (ja) 2014-03-26 2021-04-06 成長分化因子１５（ｇｄｆ－１５）に対するモノクローナル抗体およびがん悪液質およびがんを処置するためのその使用

Publications (3)

Publication Number Publication Date
JP2017508475A JP2017508475A (ja) 2017-03-30
JP2017508475A5 true JP2017508475A5 (enExample) 2018-05-17
JP6865585B2 JP6865585B2 (ja) 2021-04-28

Family

ID=52745885

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2016559286A Active JP6865585B2 (ja) 2014-03-26 2015-03-26 成長分化因子１５（ｇｄｆ−１５）に対するモノクローナル抗体およびがん悪液質およびがんを処置するためのその使用
JP2021064572A Active JP7607498B2 (ja) 2014-03-26 2021-04-06 成長分化因子１５（ｇｄｆ－１５）に対するモノクローナル抗体およびがん悪液質およびがんを処置するためのその使用
JP2023062338A Withdrawn JP2023098966A (ja) 2014-03-26 2023-04-06 成長分化因子１５（ｇｄｆ－１５）に対するモノクローナル抗体およびがん悪液質およびがんを処置するためのその使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021064572A Active JP7607498B2 (ja) 2014-03-26 2021-04-06 成長分化因子１５（ｇｄｆ－１５）に対するモノクローナル抗体およびがん悪液質およびがんを処置するためのその使用
JP2023062338A Withdrawn JP2023098966A (ja) 2014-03-26 2023-04-06 成長分化因子１５（ｇｄｆ－１５）に対するモノクローナル抗体およびがん悪液質およびがんを処置するためのその使用

Country Status (22)

Country Link
US (5) US20170204174A1 (enExample)
EP (3) EP3122775B1 (enExample)
JP (3) JP6865585B2 (enExample)
KR (1) KR102520978B1 (enExample)
CN (1) CN106536553B (enExample)
AU (2) AU2015238264B2 (enExample)
BR (1) BR122023027559A2 (enExample)
CY (1) CY1122456T1 (enExample)
DK (2) DK3122775T3 (enExample)
ES (2) ES2763859T3 (enExample)
FI (1) FI3653644T3 (enExample)
HR (2) HRP20200034T1 (enExample)
HU (2) HUE064573T2 (enExample)
IL (2) IL248038B (enExample)
LT (2) LT3653644T (enExample)
NZ (1) NZ724649A (enExample)
PL (2) PL3653644T3 (enExample)
PT (2) PT3653644T (enExample)
RS (1) RS59700B1 (enExample)
SI (1) SI3122775T1 (enExample)
SM (1) SMT202000064T1 (enExample)
WO (1) WO2015144855A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3122775T3 (da) 2014-03-26 2020-02-03 Univ Wuerzburg J Maximilians Monoklonale antistoffer til vækst- og differentieringsfaktor 15 (gdf-15), og anvendelser deraf til behandling af cancer kakeksi og cancer
DK3197493T3 (da) 2014-09-25 2021-05-31 Aveo Pharmaceuticals Inc Fremgangsmåder til omvendelse af kakeksi og forlængelse af overlevelse omfattende indgivelse af en gdf15-modulator og et anti-kræftmiddel
EP3355919B1 (en) 2015-10-02 2022-12-07 Julius-Maximilians-Universität Würzburg Combination therapy using inhibitors of human growth and differentiation factor 15 (gdf-15) and immune checkpoint blockers
GB201517528D0 (en) * 2015-10-02 2015-11-18 Julius Maximillians Universitãt Würzburg GDF-15 as a diagnosis marker for melanoma
EP3356827B1 (en) * 2015-10-02 2023-12-06 Julius-Maximilians-Universität Würzburg Gdf-15 as a diagnostic marker to predict the clinical outcome of a treatment with immune checkpoint blockers
JP7138567B2 (ja) * 2016-04-27 2022-09-16 ノバルティス アーゲー 成長分化因子１５に対する抗体およびそれらの使用
JP7059494B2 (ja) * 2016-07-06 2022-04-26 ナショナル リサーチ カウンシル オブ カナダ 血液脳関門を通過するヒト化抗体及びその使用
EP3526346A1 (en) * 2016-10-12 2019-08-21 Janssen Biotech, Inc. Methods for screening for modulators of gdf15-like biological activity
EP3551214B1 (en) * 2016-12-06 2024-03-13 St Vincent's Hospital Sydney Limited Treatment of obesity and eating disorders
AU2019323790A1 (en) * 2018-08-20 2021-03-11 Pfizer Inc. Anti-GDF15 antibodies, compositions and methods of use
AU2021376864A1 (en) * 2020-11-10 2023-06-29 Catalym Gmbh Anti-gdf15 antibody and a dosage regimen for the treatment of cancer
WO2022207846A1 (en) 2021-03-31 2022-10-06 Cambridge Enterprise Limited Therapeutic inhibitors of gdf15 signalling
WO2023018803A1 (en) 2021-08-10 2023-02-16 Byomass Inc. Anti-gdf15 antibodies, compositions and uses thereof
WO2023122213A1 (en) 2021-12-22 2023-06-29 Byomass Inc. Targeting gdf15-gfral pathway cross-reference to related applications
US20250092124A1 (en) * 2022-01-26 2025-03-20 Yunnan Baiyao Group Co., Ltd. Antibody molecule against growth and differentiation factor 15 and use thereof
CN119487065A (zh) 2022-05-09 2025-02-18 舒泰神（北京）生物制药股份有限公司 特异性识别gdf15的抗体及其应用
CN116462757A (zh) * 2023-03-24 2023-07-21 科兴生物制药股份有限公司 Gdf15的单域抗体及其应用
CN118878677A (zh) * 2024-09-29 2024-11-01 江苏凯基生物技术股份有限公司 一种IgM亚型单克隆抗体及其制备方法和应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0953639A1 (en) * 1998-04-30 1999-11-03 Boehringer Ingelheim International GmbH FAPalpha-specific antibody with improved producibility
US6455677B1 (en) * 1998-04-30 2002-09-24 Boehringer Ingelheim International Gmbh FAPα-specific antibody with improved producibility
US6465181B2 (en) 1999-03-25 2002-10-15 Abbott Laboratories Reagents and methods useful for detecting diseases of the prostate
ES2275513T3 (es) 1999-05-17 2007-06-16 Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Und Zum Vertrieb Von Pharmaka Mbh Propiedades neuroprotectoras de gdf-15, un miembro de la superfamilia de tgf-beta.
WO2002020759A2 (en) 2000-09-08 2002-03-14 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A non-steroidal anti-inflammatory drug activated gene with anti-tumorigenic properties
BRPI0506726B8 (pt) * 2004-01-07 2021-05-25 Chiron Corp anticorpo monoclonal específico para m-csf e usos deste
ES2518865T3 (es) * 2004-04-13 2014-11-05 St Vincent's Hospital Sydney Limited Agente de inhibición de MIC-1
JP2010536717A (ja) * 2007-08-16 2010-12-02 セントビンセンツ ホスピタル シドニー リミテッド マクロファージ阻害性サイトカイン（ｍｉｃ−１）活性を調節するための作用物質及び方法
US20100266707A1 (en) * 2007-10-09 2010-10-21 Samuel Norbert Breit Method of treating cachexia with the removal or inactivation of macrophage inhibitory cytokine-1
ES2493042T3 (es) 2008-09-29 2014-09-11 Roche Glycart Ag Anticuerpos contra la IL-17 humana y usos de los mismos
US20120309697A1 (en) 2009-10-28 2012-12-06 Samuel Norbert Breit Methods of diagnosing and prognosing colonic polyps
US9212221B2 (en) * 2010-03-03 2015-12-15 Detroit R & D, Inc. Form-specific antibodies for NAG-1 (MIC-1, GDF-15), H6D and other TGF-β subfamily and heart disease and cancer diagnoses
EP3318633A1 (en) 2010-11-17 2018-05-09 Chugai Seiyaku Kabushiki Kaisha Multi-specific antigen-binding molecule having alternative function to function of blood coagulation factor viii
US8790651B2 (en) * 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
CN102321173B (zh) 2011-08-12 2013-04-03 中国医学科学院肿瘤研究所 人源化巨噬细胞抑制因子1单克隆抗体及其应用
EP2565262A1 (en) 2011-08-31 2013-03-06 VTU Holding GmbH Protein expression
BR112014018575A2 (pt) 2012-01-26 2017-07-04 Amgen Inc polipetídeos de fator de diferenciação de crescimento 15 (gdf-15)
SG11201502279YA (en) * 2012-09-26 2015-04-29 Julius Maximilians Universität Würzburg Monoclonal antibodies to growth and differentiation factor 15 (gdf-15)
WO2014100689A1 (en) * 2012-12-21 2014-06-26 Aveo Pharmaceuticals, Inc. Anti-gdf15 antibodies
DK3122775T3 (da) 2014-03-26 2020-02-03 Univ Wuerzburg J Maximilians Monoklonale antistoffer til vækst- og differentieringsfaktor 15 (gdf-15), og anvendelser deraf til behandling af cancer kakeksi og cancer

Similar Documents

Publication Publication Date Title
JP2017508475A5 (enExample)
CY1124771T1 (el) Αντισωματα εναντι-σορτιλiνης και μεθοδοι χρησης αυτων
HRP20200034T1 (hr) Monoklonska protutijela protiv čimbenika rasta i diferencijacije 15 (gdf-15), te njihova upotreba u liječenju kaheksije uzrokovane rakom i raka
SA522431672B1 (ar) Cd3 أجسام مضادة للارتباط بـ
EA201891178A1 (ru) Биспецифичные молекулы, обладающие иммунореактивностью в отношении pd-1 и ctla-4, и способы их применения
NZ740686A (en) Therapeutic cd47 antibodies
NZ610734A (en) Human antibodies to the glucagon receptor
EA201791270A1 (ru) Модифицированные april-связывающие антитела
EA202091590A1 (ru) Антитела против pd-l1 и варианты их применения
MY190771A (en) Anti-pd-l1 antibodies and uses thereof
EA201891435A1 (ru) Гуманизированные моноклональные антитела, моноклональные антитела мыши или химерные моноклональные антитела против cd47
EA201600276A1 (ru) Анти-il-17-антитела, способ их получения и способ применения
MX392340B (es) Anticuerpo anti cd73 humana.
PH12016501212A1 (en) Human anti-il-33 neutralizing monoclonal antibody
HRP20170568T1 (hr) Protutijela anti-ox40 i postupci za njihovu uporabu
PE20181054A1 (es) Anticuerpos anti-cd19 humano humanizados y metodos de utilizacion
MX2009009194A (es) Anticuerpos ox40 antagonistas y su uso en el tratamiento de enfermedades inflamatorias y autoinmunes.
EA201691438A1 (ru) Антитело, которое связывается с erbb-2 и erbb-3
RU2016100892A (ru) Антитела против tweakr и их применение
NZ629829A (en) Anti-c5a antibodies and methods for using the antibodies
PH12020551012A1 (en) Monoclonal antibodies and methods for using same
UA115781C2 (uk) Cx3cr1-зв'язуючий поліпептид
RU2017113732A (ru) Антитело, которое обладает способностью нейтрализовать субстанцию, обладающую активностью, альтернативной функции фактора свертывания viii (fviii)
MY205967A (en) Monoclonal antibodies against the beta chain region of human trbv9
MY206214A (en) Monoclonal antibodies that bind specifically to human trbv9